๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Leeds
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Leeds

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 20 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to
316 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Active, closed
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
NCT03673501Gastrointestinal Stromal Tumors
Deciphera Pharmaceuticals, LLC
Phase 3
453
Glasgow, Leeds, London, Sheffield
2019-02-08
Active, closed
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.
NCT03616587ER+ HER2- Advanced Breast Cancer
AstraZeneca
Phase 1
396
Cambridge, Leeds, London, Manchester, Sutton
2018-10-11
Active, closed
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318Atopic Dermatitis
AbbVie
Phase 3
1,533
London, Oxford, Dundee, Glasgow, Leeds
2018-08-09
Recruiting
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
NCT02991469Juvenile Idiopathic Arthritis
Sanofi
Phase 2
51
London, Leeds, Liverpool
2018-08-09
Recruiting
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
NCT03435796Neoplasms
Celgene
Phase 2/3
1,541
Leeds, London, Manchester Withington, Shirley Southampton
2018-07-19
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
565
Aberdeen, London, Sutton, Cambridge, Coventry, Dundee, Leeds, Manchester
2018-06-21
Active, closed
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
pharmaand GmbH
Phase 3
1,097
Canterbury, Cliftonville, Brighton, Bristol, Cambridge, Edinburgh, Lancaster, Leeds
2018-05-14
Active, closed
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT03462719Leukemia, Lymphocytic, Chronic, B-Cell
Janssen Research & Development, LLC
Phase 3
211
Birmingham, Cambridge, Charterhouse Square, Glasgow, Leeds, Plymouth, Romford, Sheffield
2018-04-17
Active, closed
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
NCT03363373Neuroblastoma
Y-mAbs Therapeutics
Phase 2
122
Glasgow, Leeds, Southampton
2018-04-03
Active, closed
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
NCT03423628Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
AstraZeneca
Phase 1
159
Cambridge, Glasgow, Leeds
2018-04-02
Active, closed
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT03328273Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Recruiting
The EMPOWER Trial - The Carillon Mitral Contour Systemยฎ in Treating Heart Failure With FMR
NCT03142152Functional Mitral Regurgitation, Heart Failure, Mitral Valve Insufficiency, Heart Diseases
Cardiac Dimensions, Inc.
Not applicable
300
Leeds
2018-01-01
Active, closed
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeiGene
Phase 3
590
Birmingham, Bournemouth, Cambridge, Canterbury, Greater Manchester, Leeds, London, Maidstone
2017-10-31
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
Replimune, Inc.
Phase 2
340
Leeds, Oxford, Glasgow, Bebington, London, Southampton
2017-09-20
Active, closed
ATTUNEยฎ Revision- Complex Primary in Total Knee Arthroplasty Population
NCT03153449Primary Knee Arthroplasty
DePuy Orthopaedics
Not applicable
400
Basingstoke, Kirkcaldy, Leeds, Middlesbrough, Oswestry, Oxford, Wigan
2017-09-19
Active, closed
ATTUNE Revision System in the Revision Total Knee Arthroplasty Population
NCT03153475Revision Total Knee Arthroplasty
DePuy Orthopaedics
Not applicable
400
Basingstoke, Kirkcaldy, Leeds, North Yorks, Oswestry, Oxford, Wigan
2017-05-30
Active, closed
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
NCT03229200Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease
Pharmacyclics Switzerland GmbH
Phase 4
297
Cardiff, Leeds, London, Manchester
2017-05-22
Active, closed
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT02773030Multiple Myeloma
Celgene
Phase 1/2
466
Birmingham, Leeds, Oxford, Sutton
2016-10-14
Active, closed
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT02811861Renal Cell Carcinoma
Eisai Inc.
Phase 3
1,069
Bournemouth, Cardiff, Edinburgh, Glasgow, Leeds, London, Manchester
2016-10-13
Active, closed
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 2
60
Bournemouth, Leeds, Manchester
2016-03-08
Active, closed
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
NCT02598661Myelodysplastic Syndromes
Geron Corporation
Phase 2/3
289
Leeds, Nottingham, Southampton, Aberdeen
2016-01-12
Active, closed
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
NCT02516241Urothelial Cancer
AstraZeneca
Phase 3
1,126
Cambridge, Cardiff, Glasgow, Leeds, London, Manchester, Metropolitan Borough of Wirral, Sheffield
2015-11-02
Active, closed
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
533
Birmingham, Bournemouth, Cambridge, Cardiff, Greater London, Hull, Leeds, Leicester
2015-07-28
Active, closed
Micra Transcatheter Pacing System Post-Approval Registry
NCT02536118Bradycardia
Medtronic
Observational
3,100
Birmingham, Bristol, Leeds, Leicester, Liverpool, London, Manchester, Middlesbrough
2015-07
Active, closed
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naรฏve CLL
NCT02475681Chronic Lymphocytic Leukemia
Acerta Pharma BV
Phase 3
535
Bournemouth, Cambridge, Leeds, Leicester, London, Plymouth, Southampton, Truro
2015-06-26
Rows per page Showing 276–300 of 316
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/leeds

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.